ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 242,07
0,08%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) Actualités

LXRX Lexicon Pharmaceuticals Inc

1,80
-0,03 (-1,64%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Lexicon Pharmaceuticals Inc LXRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,03 -1,64% 1,80 06:00:01
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,83 1,78 1,875 1,82 1,83
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202414:00GLOBEFindings on the Burdens of Diabetic Peripheral Neuropathic..
29/5/202413:30GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
16/5/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
14/5/202423:05EDGAR2Form SC 13D/A - General statement of acquisition of..
14/5/202413:00GLOBENew Post-Hoc Analysis of Pooled Phase 3 Data Shows That..
13/5/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202423:14EDGAR2Form S-3/A - Registration statement under Securities Act of..
10/5/202422:15EDGAR2Form 8-K - Current report
09/5/202413:30GLOBELexicon Pharmaceuticals to Participate in the Bank of..
02/5/202422:05GLOBELexicon Pharmaceuticals Reports First Quarter 2024 Financial..
29/4/202415:00GLOBELonnel Coats Retires as Chief Executive Officer and Board..
29/4/202413:00GLOBELexicon Pharmaceuticals to Host First Quarter 2024 Financial..
18/4/202414:00GLOBELexicon Pharmaceuticals to Host 2024 Investor Day
03/4/202414:00GLOBELexicon Pharmaceuticals to Participate in the 23rd Annual..
25/3/202414:20GLOBEClinical Data on the Impact of Sotagliflozin on Stroke and..
12/3/202413:00GLOBENew Post Hoc Analysis of inTandem3 Study Demonstrates..
11/3/202421:25EDGAR2Form PRE 14A - Other preliminary proxy statements
11/3/202412:26EDGAR2Form 8-K - Current report
11/3/202412:15GLOBELexicon Pharmaceuticals Reports Fourth Quarter..
11/3/202412:05GLOBELexicon Announces Oversubscribed $250 Million Private..
11/3/202412:00GLOBELexicon Preparing to Resubmit Sotagliflozin NDA for Type 1..
29/2/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:00GLOBELexicon Pharmaceuticals Provides Business and Pipeline..
29/12/202323:29EDGAR2Form 8-K - Current report
29/12/202323:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/12/202322:04EDGAR2Form 8-K - Current report
21/12/202322:15GLOBELexicon Pharmaceuticals To Participate In The 42nd Annual..
30/11/202313:30GLOBELexicon Enrolls First Patient in Phase 2b Progress Study of..
22/11/202313:30GLOBELexicon Pharmaceuticals to Participate in the 35th Annual..
17/11/202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202323:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202320:10GLOBEINPEFA® (sotagliflozin) Use Associated With Early Clinical..
10/11/202322:01GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
08/11/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:22EDGAR2Form 8-K - Current report
08/11/202313:00GLOBELexicon Pharmaceuticals Reports Third Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
LXRX
Lexicon Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés